Press Releases

Back to previous page

ReGen Biologics Launches New Website

Provides Patients Worldwide with Resource for Information on Repair and Regeneration of Damaged Knee Tissue

Franklin Lakes, NJ – March 19, 2003 – ReGen Biologics, Inc. (OTC: RGBI), a tissue remodeling company specializing in the treatment of knee injuries, today announced the launch of its new website, www.regenbio.com.  Redesigned as an information portal, the ReGen website educates visitors on treatment alternatives for meniscus injuries, ReGen's unique tissue regeneration technology, as well as industry news and information.

The website is designed to provide specialized and detailed subject matter to consumers, patients, surgeons, investors, and distributors regarding ReGen's tissue remodeling technology and state-of-the-art techniques for regenerating tissue, restoring mobility and rejuvenating lifestyles for patients with meniscus injuries of the knee.

"Our goal with the website is to establish an online source for the latest information on knee tissue injuries and treatments,” said Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO of ReGen. "With features such as a tutorial on meniscus tissue injuries, frequently asked questions, and extensive links to related websites, we have developed a tool for educating visitors about their tissue repair alternatives, including our CMI procedure."

ReGen's flagship product, the CMI, is a type I collagen implant designed for patients with an irreparable meniscus tear or loss of meniscus tissue, typically through an arthroscopic partial meniscectomy procedure. The purpose of the CMI is to assist patients to regain mobility and return to a more vigorous lifestyle, while forestalling or minimizing degenerative joint disease.

About ReGen Biologics, Inc.
ReGen Biologics is a tissue remodeling company that develops products that restore injured tissue.  When applied to orthopaedics, ReGen's patented core technology has resulted in the CMI, which uses the body’'s own healing process to grow healthy new meniscus tissue and restore mobility for patients with certain knee injuries.  ReGen has recently completed enrollment in its U.S. Multicenter Clinical Trial of the CMI.  The CMI is currently distributed in Europe, Australia, Chile and certain other countries through Centerpulse (NYSE: CEP) and it is expected to be selectively available in Canada during 2003.

For more information on ReGen’'s next generation tissue regeneration products, visit www.regenbio.com, call 201-651-5140, or email info@regenbio.com.


Contact:
Katrina Pruitt-Andrews
KPA Marketing & Public Relations
301-604-7377 direct; 301-704-4087 cell
Kpandrews@comcast.net


Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the managements of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's current report on Form 8-K/A, filed with the Securities and Exchange Commission on September 4, 2002. ReGen's filings with the SEC are available to the public from commercial document-retrieval services and at the Web site maintained by the SEC at http://www.sec.gov.